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Abstract
AIM: Although liver cirrhosis is a predisposing factor for
hepatocellular carcinoma (HCC), relatively few reports are
available on HCC in primary biliary cirrhosis. High plasma
nociceptin (N/OFQ) level has been shown in Wilson disease
and in patients with acute and chronic pain.
METHODS: We report a follow-up case of HCC, which
developed in a patient with primary biliary cirrhosis. The tumor
appeared 18 years after the diagnosis of PBC and led to death
within two years. Alfa fetoprotein and serum nociceptin levels
were monitored before and during the development of HCC.
Nociceptin content was also measured in the tumor tissue.
RESULTS: The importance and the curiosity of the presented
case was the novel finding of the progressive elevation of
plasma nociceptin level up to 17-fold (172 pg/mL) above the
baseline (9.2±1.8 pg/mL), parallel with the elevation of alpha
fetoprotein (from 13 ng/mL up to 3 480 ng/mL) during tumor
development. Nociceptin content was more than 15-fold higher
in the neoplastic tissue (0.16 pg/mg) than that in the tumor-
free liver tissue samples (0.01 pg/mg) taken during the autopsy.
CONCLUSION: Results are in concordance with our previous
observation that a very high plasma nociceptin level may be
considered as an indicator for hepatocellular carcinoma.
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INTRODUCTION
The incidence of hepatocellular carcinoma (HCC) in primary
biliary cirrhosis (PBC) is reported to range from 0.5% to 4.2%,
which is somewhat less frequent than that in liver cirrhosis
from other etiologies[1,2]. However, recent reports have shown
an increasing trend. The incidence of HCC was found higher
in stage III/IV than in stage I/II patients[1,3,4].
      Relatively few prospective and comprehensive studies are
available on HCC in PBC, and the number of case reports is
also limited. Summarizing the data of the literature, 126 of
6 188 PBC patients (2.0%) were found to have HCC. Since
HCC usually develops many years after the diagnosis of PBC,
screening of HCC has clinical importance and offers best with
hope for early detection. Serum AFP is a widely accepted
marker of HCC[5]; however, using the conventional cut-off
value of 500 ng/mL, it has a sensitivity of about 50% and a
specificity of more than 90% in detecting HCC in a patient
with coexisting liver disease[6]. The average survival of patients
with HCC improved in the last decades[7]. Female HCC patients
often have a better prognosis than male patients[8]. Because of
the lack of sensitive markers of malignant hepatic tumors, HCC
is usually recognized in the advanced stage.
     We reported a follow-up case of HCC in a PBC patient.
The importance of this case is the novel finding of progressive
elevation in plasma nociceptin (N/OFQ, formerly named as
orphanin FQ) up to 17-fold above the baseline, parallel with
the elevation of alpha fetoprotein (AFP) during tumor
development. Moreover, high nociceptin content was found
in the tumor tissue as well.
    Nociceptin, a newly discovered neuropeptide of 17
aminoacids, is the natural agonist of NOP receptor, earlier
named opioid receptor-like 1 (ORL1) receptor. N/OFQ is a
neuropeptide that is endowed with pronociceptive activity in
vivo. Both the long and the short splice variants of the OP4
receptor mRNA were isolated in rat liver[9]; however, there are
no data about its physiological or pathophysiological role in
liver function. To date only few clinical studies on nociceptin
were reported, and only one of them dealt with liver disease.
      Findings of the presented case are in concordance with our
previous observation that a high plasma NC level may be an
indicator of HCC.
CASE REPORT
A 47-year-old woman was admitted for fatigue, itching,
hepatomegaly, high alkaline phophatase and gamma-GT levels.
Primary biliary cirrhosis was diagnosed based on the clinical
symptoms, laboratory findings, AMA M2 positivity, normal
US and ERCP pictures. Liver biopsy revealed stage II/III. There
was no family history of liver disease or autoimmune disease,
and all other confounding risk factors including alcohol, HBV
and HCV infections were excluded. The patient was a heavy
smoker. The past surgical history was significant only for an
appendectomy and two caesarean sections. Her menopause
started at the age of 38. Bone mineral density was slightly
below the normal range at the time of diagnosis of PBC.
Ursodeoxycholic acid (Ursofalk) treatment, calcium and
vitamin D supplementation were introduced.
     Severe progression of osteoporosis was observed during
the following years. Five years after the diagnosis of PBC
significantly decreased bone mineral density was shown both
on the femoral neck (T-score: -5.12, Z score: -3.38) and on the
lumbar vertebrae (T-score: -5.44, Z-score: -3.9). At the age of
57 despite the calcium, vitamin-D supplementation, calcitonin
and bisphophonate (Fosamax) treatment, the severe osteoporosis
led to hip fracture and multiple vertebral collapses, which made
the patient lifelong disabled.
      Progression of PBC to stage IV occured. She was monitored
by yearly US, by regular laboratory tests and AFP every 3-4
months. For different reasons we collected blood samples for
plasma nociceptin level determination as well. Sampling was
done in conformity to accepted ethical standards and was
approved by the regional ethical committee.
     Hepatocellular carcinoma developed 18 years after the
diagnosis of PBC. Regular follow-up US investigations
revealed a focal lesion of 2.5 cm in diameter, which increased
rapidly in segment V of the liver. Fine needle biopsy findings
proved hepatocellular carcinoma. After the HCC diagnosis a
continuous and rapid increase in the size of the tumor, an
elevation of ALP, GGT, plasma nociceptin and AFP levels
and clinical deterioration were observed.
Figure 1  Serum alpha fetoprotein and plasma nociceptin lev-
els before and during the development of hepatocellular carci-
noma in the presented patient with primary biliary cirrhosis.
Figure 2  Hepatocellular carcinoma in the presented patient
with primary biliary cirrhosis. A: Gross view of liver at autopsy.
Grayish nodules of carcinoma protrude on the surface of the
cirrhotic liver. Bar=1 cm. B: The focal red staining on the histo-
logic picture of the hepatocellular carcinoma shows the immu-
nohistochemical reaction of AFP. Original magnification 400×.
     The AFP value had been within the normal range one year
before the tumor was detected (13 ng/mL), but it was elevated
at the time of the diagnosis of HCC (426 ng/mL) and rose up to
3 480 ng/ml. The plasma nociceptin measured by radioimmunoassay
125I-Nociceptin-kit, Phoenix Pharmaceuticals, Phoenix, CA,
USA (10.6 pg/mL) was within the normal range (9.2±1.8 pg/mL)
in the tumor-free stage, while progressive elevation was detected
during the tumor development (15.8, 65.8, 103.7, 128.0,
172.2 pg/mL), reaching the highest value before death (Figure
1). Higher nociceptin content was measured in the tumor tissue
(0.16 pg/mg) compared to the tumor-free liver tissue sample
(0.01 pg/mg) taken during the autopsy. The patient refused any
surgical or other systemic or local tumor treatment. The size of
the tumor increased up to 12 cm in diameter and involved
segments V, VII, VIII and partly IV. No metastasis was detected,
but necrosis developed in the central region of the tumor. The
patient received supportive treatment, analgetics, and died of
tumorous cachexia 19 months after the discovery of HCC. The
autopsy confirmed both PBC stage IV and HCC. Focal presence
of AFP was shown in the tumor by immunohistochemistry
(Figures 2 A and B).
      A nociceptin content in the HCC tissue (0.16 pg/mg) was
15-fold higher than that in the tumor free liver tissue sample
(0.01 pg/mg) taken during the autopsy.
DISCUSSION
The presented case is a further example of the occurrence of
HCC in PBC, and it supports previous observations that HCC
usually develops in stage III/IV patients[3]. The tumor developed
18 years after the diagnosis of PBC and led to the death of the
patient within two years. Furthermore, severe osteoporosis is
a common disorder in PBC, although recently it is considered
as a non-specific complication[10,11 ]. In our patient the early
menopause together with PBC resulted in many bone fractures
causing lifelong disability. The low serum osteocalcin level
indicated a low turnover osteoporosis. High serum osteoprotegerin
and low RANKL have been reported in PBC[12], and we found
the same alteration in this patient. Progression of bone loss was
detected despite the serum osteoprotegerin was two-fold higher
than normal, which suggested that inflammatory process in the
liver could also contribute to the elevation of osteoprotegerin.
    This is the first follow-up case in which progressive
elevation of plasma nociceptin level was detected in parallel
with the elevation of AFP during tumor development, and high
N/OFQ content was found in the tumor tissue.
     Nociceptin is the endogenous agonist of a G-protein
coupled, naloxon insensitive opioid-like 1 receptor (ORL1)
recently named as OP4. Although nociceptin is structurally
related to opioid peptides, especially to dynorphin A, it does
not interact with m, d and k receptors. N/OFQ/OP4 system is a
newly discovered peptide-based signalling pathway, involved
in the modulation of pain and cognition. Opioid antagonists
were successfully used for the treatment of pruritus in patients
with PBC[13]. These results together with the data that high
plasma N/OFQ level has been reported in Wilson disease and
in patients with chronic pain, led us to measure plasma
nociceptin level in primary biliary cirrhosis[14]. Our motivation
was reinforced by an accidental observation that we found
extremely high N/OFQ in a Wilson patient with advanced HCC.
     The nociceptin levels in blood samples collected in the
pre-tumor stage and during the tumor development period
clearly showed that the elevation of N/OFQ was parallel with
that of AFP and the clinical deterioration. When the tumor
was first detected the N/OFQ level was 6-fold higher than that
in healthy controls (65.8 versus 9.2±1.8 pg/mL, n=29) and in
other PBC patients without HCC (12.1±3.2pg/mL, n=21).
When the tumor reached 11 cm the N/OFQ level was 17-fold
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higher than normal. Since N/OFQ content was 15-fold higher
in tumor tissue than in tumor free parts of the liver, the question
arose whether nociceptin was produced by HCC tissue or it
accumulated in the tumor by passive binding or via increased
nociceptin receptor expression.
     Further research is needed to clarify the mechanism and
clinical significance of the highly elevated N/OFQ level in
HCC. Since N/OFQ transcripts are expressed in immune
cells[15], the high N/OFQ level may also be an indicator of
altered reaction of the body including immunological,
cytokine and other mechanisms.
     Elevated N/OFQ level might represent a compensatory
mechanism in the N/OFQ/OP4 system to modulate pain
perception in the central nervous system. This mechanism could
explain why some patients with a very high plasma N/OFQ
level did not have pain despite advanced stage of malignant
liver tumor. It is remarkable that the N/OFQ was 3-fold higher
in our patient than the highest values reported in patients with
chronic pain without malignant disease[16].
    In conclusion, the novel finding of this study is that
progressive elevation of plasma nociceptin was detected in
parallel with the elevation of AFP during tumor development,
as well as high N/OFQ content was found in the tumor tissue
in a PBC patient with hepatocellular carcinoma. This is in
concordance with our previous observation that high plasma
N/OFQ level might be considered as an indicator of HCC.
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